LL-37 and the Gut Microbiome

LL-37 Gut Defense

37 amino acids

LL-37, the only human cathelicidin, kills pathogenic bacteria in the gut while sparing beneficial commensals through selective membrane targeting and concentration gradients.

Iimura et al., J Immunology, 2005

Iimura et al., J Immunology, 2005

View as image

Your gut contains approximately 38 trillion bacteria, and a single antimicrobial peptide stands between that community and the intestinal wall. LL-37, the only cathelicidin in humans, is produced by intestinal epithelial cells, neutrophils, and macrophages within the gut mucosa. It kills bacteria by punching holes in their membranes, a mechanism that should theoretically destroy beneficial bacteria alongside pathogens. Yet the gut microbiome persists, and in many cases, LL-37 expression appears to support rather than damage microbial diversity.^[1] This paradox, how an antimicrobial peptide can defend against infection without sterilizing the gut, is central to understanding how LL-37 protects the intestines. The answer involves concentration gradients, selective membrane chemistry, biofilm tolerance, and immunomodulation that collectively make LL-37 more of a microbiome curator than a broad-spectrum antibiotic. For the broader picture of how gut bacteria produce their own antimicrobial peptides and the concept of antimicrobial peptides and microbiome balance, the cross-cluster articles provide essential context.

How LL-37 Kills Bacteria

LL-37 is a 37-amino-acid cationic peptide with an amphipathic alpha-helical structure. The positive charge (net +6) allows it to bind electrostatically to the negatively charged lipopolysaccharide (LPS) of Gram-negative bacteria and the lipoteichoic acid of Gram-positive bacteria. Once bound, the hydrophobic face of the helix inserts into the lipid bilayer, creating pores or disrupting membrane integrity.^[2]

This mechanism works against both Gram-positive and Gram-negative bacteria, including multi-drug-resistant strains. Bucki et al. (2010) reviewed LL-37 as a "multitask antimicrobial peptide," noting that it also neutralizes bacterial toxins, disrupts biofilms, and modulates immune cell recruitment.^[3]

The speed is notable: LL-37 kills bacteria within minutes, faster than conventional antibiotics that require bacterial protein synthesis or DNA replication. This rapid killing makes resistance development difficult because the target (the bacterial membrane) is a fundamental structural component that cannot be easily modified without compromising bacterial viability.

Why LL-37 Does Not Destroy the Microbiome

If LL-37 kills bacteria by attacking their membranes, why does it not wipe out the entire gut microbiome? Several mechanisms explain this selectivity:

Concentration gradients: LL-37 is secreted by epithelial cells and accumulates at highest concentrations immediately adjacent to the intestinal wall. The concentration decreases rapidly with distance into the lumen. Commensal bacteria that maintain a respectful distance from the epithelium (in the outer mucus layer) encounter sub-lethal concentrations, while pathogens that breach the inner mucus layer and contact the epithelium face bactericidal levels.

Membrane composition differences: Not all bacterial membranes are equally susceptible. Some commensal species incorporate modifications into their lipid A (a component of LPS) that reduce the negative surface charge, making them less attractive to cationic LL-37. Pathogens that have evolved to invade host tissue often have membrane compositions that make them more vulnerable.

Mucus layer protection: The mucus layer that lines the intestinal epithelium sequesters LL-37 and limits its diffusion into the lumen. This creates a functional gradient where the peptide concentration is highest at the tissue-mucus interface (defending against breach) and lowest in the luminal space where commensals reside.

Salt sensitivity: LL-37's antimicrobial activity is reduced at physiological salt concentrations. The luminal environment of the gut has varying ionic strength, and regions with higher salt concentration may partially neutralize LL-37's activity, providing another layer of protection for luminal bacteria.

Targeted Defense: The H. pylori Evidence

Hase et al. (2003) demonstrated that LL-37 expression in the stomach is directly triggered by Helicobacter pylori colonization. Gastric epithelial cells upregulate cathelicidin production specifically in response to this pathogen, creating a localized antimicrobial response at the infection site.^[4]

This is not a generalized antimicrobial response. The epithelium detects the pathogen through pattern recognition receptors (TLRs, NODs) and responds with targeted LL-37 secretion. The peptide concentration rises locally, attacking the adhering pathogen, while distant microbiome populations remain unaffected.

Cathelicidin Deficiency: What Happens Without LL-37

The most direct evidence for LL-37's protective role comes from cathelicidin-knockout mice. Iimura et al. (2005) showed that mice lacking the cathelicidin gene (CRAMP, the mouse ortholog of human LL-37) had increased susceptibility to intestinal infection with Citrobacter rodentium, an adherent bacterial pathogen that models enteropathogenic E. coli infection in humans.^[1]

The cathelicidin-deficient mice developed more severe colitis, higher bacterial loads in the intestinal tissue, and greater barrier disruption. When synthetic CRAMP was administered, protection was partially restored. This demonstrates that cathelicidin is not redundant with other antimicrobial mechanisms; its loss creates a measurable deficit in intestinal defense.

Beyond Killing: LL-37's Barrier-Protective Effects

Otte et al. (2009) investigated LL-37's effects on intestinal epithelial barrier integrity and found that the peptide modulates tight junction protein expression, independently of its antimicrobial activity.^[5] LL-37 influenced the expression of claudins, occludin, and ZO-1, proteins that seal the spaces between epithelial cells and prevent bacterial translocation.

This means LL-37 protects the gut through at least two mechanisms: killing bacteria that reach the epithelial surface and strengthening the physical barrier that prevents bacteria from crossing in the first place. The intestinal barrier role of cathelicidin is explored in detail in the sibling article.

Fabisiak et al. (2016) reviewed LL-37's pleiotropic activities in the gastrointestinal context: chemotaxis of neutrophils, monocytes, and T cells to infection sites; stimulation of angiogenesis for wound healing; modulation of cytokine production; and direct effects on epithelial cell proliferation and survival.^[6] These immunomodulatory functions position LL-37 not just as a bactericidal agent but as an orchestrator of the mucosal immune response that shapes the environment in which the microbiome exists.

LL-37 and Microbiome Composition

The relationship between LL-37 and microbiome composition is bidirectional. LL-37 shapes the microbiome by selectively eliminating susceptible species, but the microbiome also regulates LL-37 expression through its metabolic products.

Short-chain fatty acids (SCFAs) produced by commensal bacteria (butyrate, propionate, acetate) stimulate cathelicidin expression in colonic epithelial cells. Butyrate, produced primarily by Faecalibacterium prausnitzii and Roseburia species, is a particularly potent inducer of LL-37. This creates a positive feedback loop: beneficial bacteria produce metabolites that increase LL-37 expression, which in turn protects those bacteria from pathogenic competitors.

Vitamin D is the primary hormonal regulator of cathelicidin expression. The vitamin D receptor (VDR) directly binds to the cathelicidin gene promoter and upregulates transcription. Vitamin D deficiency reduces LL-37 levels in the gut, potentially contributing to the association between low vitamin D status and increased susceptibility to gastrointestinal infections and inflammatory bowel disease.

The Dark Side: LL-37 and Colorectal Cancer

LL-37's relationship with gut health is not uniformly positive. Porter et al. (2021) found that increased colonic epithelial LL-37 expression was associated with progression of colorectal adenomas to carcinomas.^[7] Wlodarczyk et al. (2025) confirmed this association, reporting that elevated LL-37 in colonic tissue correlated with tumor progression in colorectal cancer.^[8]

The mechanisms may include LL-37's pro-angiogenic effects (tumors need blood vessels to grow), its ability to stimulate epithelial cell proliferation, and its modulation of inflammatory pathways that can promote tumor development. LL-37's dual role as both anti-inflammatory and pro-inflammatory is context-dependent, and in the tumor microenvironment, its effects may shift from protective to harmful.

This complexity is consistent with the broader understanding that antimicrobial peptides evolved as part of the innate immune response, which includes inflammation, tissue repair, and cell proliferation, all processes that tumors can co-opt for growth.

Limitations

The evidence for LL-37's selective effects on the microbiome is largely inferred rather than directly measured. No study has comprehensively profiled the gut microbiome before and after LL-37 administration in humans. The selectivity hypothesis is supported by logical reasoning (concentration gradients, membrane differences) and animal knockout studies, but direct evidence from human intestinal tissue is limited.

Most mechanistic studies use synthetic LL-37 at concentrations that may not reflect physiological levels in the gut. The effective concentration of LL-37 at the epithelial surface in living human intestine has not been precisely measured, making it difficult to know whether the in vitro observations are directly translatable.

The cathelicidin-knockout mouse model uses CRAMP, not human LL-37. While CRAMP and LL-37 share functional properties (cationic, alpha-helical, membrane-disrupting), their amino acid sequences differ, and species-specific differences in gut anatomy, microbiome composition, and immune regulation limit direct translation.

The association between LL-37 and colorectal cancer complicates any therapeutic narrative. If LL-37 can promote tumor growth in certain contexts, interventions that increase cathelicidin expression (vitamin D supplementation, butyrate-producing probiotics) may have unintended consequences in individuals with pre-existing colorectal neoplasia.

The Bottom Line

LL-37, the only human cathelicidin, kills pathogenic bacteria through membrane disruption while largely sparing the gut microbiome through concentration gradients, mucus layer sequestration, and differential membrane susceptibility. Beyond direct antimicrobial activity, LL-37 strengthens intestinal barrier integrity and orchestrates mucosal immune responses. The microbiome reciprocally regulates LL-37 through butyrate production, creating a cooperative relationship. The association between elevated LL-37 and colorectal cancer progression indicates that cathelicidin's effects are context-dependent and not uniformly protective.

Frequently Asked Questions

What is LL-37 and what does it do in the gut?

LL-37 is a 37-amino-acid antimicrobial peptide produced by intestinal epithelial cells, neutrophils, and macrophages. It kills bacteria by disrupting their cell membranes, neutralizes bacterial toxins, disrupts biofilms, strengthens the intestinal barrier through tight junction modulation, and recruits immune cells to infection sites. It is the only cathelicidin antimicrobial peptide in humans and is regulated by vitamin D (Bucki et al., 2010; Fabisiak et al., 2016).

Does LL-37 kill good bacteria in the gut?

LL-37 shows selectivity toward pathogens over commensal bacteria through several mechanisms. It is secreted at highest concentrations at the epithelial surface, where invading pathogens are found, while commensal bacteria in the outer mucus layer encounter sub-lethal levels. Some commensals have membrane modifications that reduce susceptibility. Cathelicidin-knockout mice show increased pathogen susceptibility without dramatic changes in commensal populations (Iimura et al., 2005).

How does vitamin D affect LL-37 in the gut?

Vitamin D directly regulates LL-37 expression through the vitamin D receptor (VDR), which binds to the cathelicidin gene promoter. Low vitamin D levels reduce LL-37 production in intestinal epithelial cells, potentially weakening gut antimicrobial defense. This connection may partly explain the association between vitamin D deficiency and increased gastrointestinal infections and inflammatory bowel disease.

Can LL-37 cause problems in the gut?

Elevated LL-37 expression in colonic tissue has been associated with colorectal cancer progression in two separate studies (Porter et al., 2021; Wlodarczyk et al., 2025). LL-37 has pro-angiogenic and pro-proliferative effects that tumors may exploit. Its role as both anti-inflammatory and pro-inflammatory depends on context. In normal gut physiology, LL-37 is protective; in the tumor microenvironment, its effects may shift to promote cancer growth.

Do probiotics increase LL-37 levels?

Commensal bacteria that produce butyrate (a short-chain fatty acid) stimulate cathelicidin expression in colonic epithelial cells. Species like Faecalibacterium prausnitzii and Roseburia are potent butyrate producers. This creates a cooperative relationship: beneficial bacteria enhance LL-37 production, which in turn protects them from pathogenic competitors. Whether commercially available probiotics meaningfully increase LL-37 levels in humans has not been definitively established.

Is LL-37 being developed as a drug for gut diseases?

LL-37 is not approved as a drug for any gut condition. Research interest is focused on understanding its natural role in intestinal defense rather than administering it as a therapeutic. Challenges include the peptide's sensitivity to salt and proteases in the gut lumen, its context-dependent effects (protective vs. tumor-promoting), and the difficulty of targeting it to specific intestinal locations. Approaches under investigation include LL-37 analogs with improved stability and nanoparticle delivery systems.